Your browser doesn't support javascript.
loading
A Novel UHPLC-MS Method Targeting Urinary Metabolomic Markers for Autism Spectrum Disorder.
Olesova, Dominika; Galba, Jaroslav; Piestansky, Juraj; Celusakova, Hana; Repiska, Gabriela; Babinska, Katarina; Ostatnikova, Daniela; Katina, Stanislav; Kovac, Andrej.
Afiliación
  • Olesova D; Institute of Neuroimmunology, Slovak Academy of Sciences, Dubravska cesta 9, 84510 Bratislava, Slovakia.
  • Galba J; Department of Pharmaceutical Analysis and Nuclear Pharmacy, Faculty of Pharmacy, Comenius University in Bratislava, Odbojarov 10, 832 32 Bratislava, Slovakia.
  • Piestansky J; Department of Pharmaceutical Analysis and Nuclear Pharmacy, Faculty of Pharmacy, Comenius University in Bratislava, Odbojarov 10, 832 32 Bratislava, Slovakia.
  • Celusakova H; Institute of Physiology, Faculty of Medicine, Comenius University in Bratislava, Sasinkova 2, 813 72 Bratislava, Slovakia.
  • Repiska G; Institute of Physiology, Faculty of Medicine, Comenius University in Bratislava, Sasinkova 2, 813 72 Bratislava, Slovakia.
  • Babinska K; Institute of Physiology, Faculty of Medicine, Comenius University in Bratislava, Sasinkova 2, 813 72 Bratislava, Slovakia.
  • Ostatnikova D; Institute of Physiology, Faculty of Medicine, Comenius University in Bratislava, Sasinkova 2, 813 72 Bratislava, Slovakia.
  • Katina S; Institute of Mathematics and Statistics, Faculty of Science, Masaryk University, Kotlárská 267/2, 611 37 Brno, Czech Republic.
  • Kovac A; Institute of Neuroimmunology, Slovak Academy of Sciences, Dubravska cesta 9, 84510 Bratislava, Slovakia.
Metabolites ; 10(11)2020 Nov 02.
Article en En | MEDLINE | ID: mdl-33147863
ABSTRACT
Autism spectrum disorder is a heterogeneous neurodevelopmental disease. Currently, no biomarker of this disease is known. Diagnosis is performed through observation, standardized behavioral scales, and interviews with parents. In practice, diagnosis is often delayed to the average age of four years or even more which adversely affects a child's perspective. A laboratory method allowing to detect the disorder at earlier stages is of a great need, as this could help the patients to start with treatment at a younger age, even prior to the clinical diagnosis. Recent evidence indicates that metabolomic markers should be considered as diagnostic markers, also serving for further differentiation and characterization of different subgroups of the autism spectrum. In this study, we developed an ultra-high performance liquid chromatography-tandem triple quadrupole mass spectrometry method for the simultaneous determination of six metabolites in human urine. These metabolites, namely methylguanidine, N-acetyl arginine, inosine, indole-3-acetic acid, indoxyl sulfate and xanthurenic acid were selected as potential biomarkers according to prior metabolomic studies. The analysis was carried out by means of reversed-phase liquid chromatography with gradient elution. Separation of the metabolites was performed on a Phenomenex Luna® Omega Polar C18 (100 × 1.0 mm, 1.6 µm) column at a flow rate of 0.15 mL/min with acetonitrile/water 0.1% formic acid aqueous as the mobile phase. The analysis was performed on a group of children with autism spectrum disorder and age-matched controls. In school children, we have detected disturbances in the levels of oxidative stress markers connected to arginine and purine metabolism, namely methylguanidine and N-acetylargine. Also, products of gut bacteria metabolism, namely indoxyl sulfate and indole-3-acetic acid, were found to be elevated in the patients' group. We can conclude that this newly developed method is fast, sensitive, reliable, and well suited for the quantification of proposed markers.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Metabolites Año: 2020 Tipo del documento: Article País de afiliación: Eslovaquia

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Metabolites Año: 2020 Tipo del documento: Article País de afiliación: Eslovaquia